FX1 iPSC

General

Cell Line

hPSCreg name WISi006-A
Cite as:
WISi006-A (RRID:CVCL_IU03)
Alternative name(s)
FX1 iPSC
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RGIe116-A
(SI-214)
Donor diseases:
Fragile X syndrome
INSRMe016-A
(STR-I-347-FRAXA)
Donor diseases:
Fragile X syndrome
RGIe041-A
(SI-125)
Donor diseases:
Fragile X syndrome
INSRMe005-A
(STR-I-189-FRAXA)
Donor diseases:
Fragile X syndrome
HUJIe001-A
(HEFX1)
Donor diseases:
Fragile X syndrome
VUBe013-A
(VUB13_FXS)
Donor diseases:
Fragile X syndrome
INSRMe002-A
(STR-I-233-FRAXA)
Donor diseases:
Fragile X syndrome
HADe005-A
(HAD 5)
Donor diseases:
Fragile X syndrome
VUBe011-A
(VUB11_FXS)
Donor diseases:
Fragile X syndrome
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Weizmann Institute of Science (WIS)
Owner Weizmann Institute of Science (WIS)
Distributors
Derivation country Israel

External Databases

BioSamples SAMEA103992705
Cellosaurus CVCL_IU03
Wikidata Q54994117

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 1-4
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
information available on Coriell repository - https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM05131&Product=CC
Synonyms
  • FXS
  • FraX syndrome
  • Martin-Bell syndrome
  • FRAXA syndrome
show more synonyms
Genetic variants
FMR1 (target)
Xq27.3
(CGG)n EXPANSION; The usual cause of the fragile X syndrome is an expanded (CGG)n repeat in the 5-prime noncoding region of the FMR1 gene. Please see fibroblast line (GM05131; Coriell Institute) for further details.
Family history no

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46XY

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA103992706

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. Coriell Repository ( https://catalog.coriell.org/0/Sections/Search/Sample_Detail.aspx?Ref=GM05131&Product=CC )
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Coriell Repository
Alternatives to consent
Alternative consent approval number
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Details on restriction to research project
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? Yes
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? No
Does consent permit access to medical records of the donor? No
Please describe how access is provided:
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Weizmann IRB and ESCRO
Approval number Format Sep 25 2015
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Weizmann IRB and ESCRO
Approval number Format Sep 25 2015
Do you have obligations to third parties in regard to the use of the cell line? No
Please describe:
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Further constraints on use
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Invitrogen LTd.
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No
Constraints for use or distribution

hIPSC Derivation

General

Source cell line name GM05131
Derived from same source line (potentially other lot and donor, see below):
Source cell type
Any skin fibroblast that is part of some dermis.
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 1-4
Source cell line vendor Coriell

Reprogramming method

Vector type Integrating
Vector Virus (Lentivirus)
Is the used vector excisable?
Yes
Absence of reprogramming vector(s)?
No
Reprogramming vectors silenced?
Yes
Methods used
Immunostaining, PCR, RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Mechanically
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
Differentiation Potency

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46XY
Passage number: 12
Karyotyping method: Spectral karyotyping

Other Genotyping (Cell Line)